Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

Summary

This study is looking at the effects of giving early treatment of deferiprone to young children with beta thalassemia who have started receiving regular blood transfusions but have not yet reached the criteria for starting on iron chelation therapy. Half the patients in the study will receive deferiprone, and the other half will receive placebo, for up to 12 months.

Timeline

Start

2018-11-09

Primary completion

2020-09-29

Completion

2020-09-29

Drugs

Indications